FOXOW FOXO TECHNOLOGIES INC.

BEARISH Impact: 6/10 8-K
Horizon weeks Filed May 22, 2026 Processed 21d 16h ago SEC 0001493152-26-025076
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)

Price Chart

Loading chart...

Executive Summary

FOXO Technologies settled outstanding obligations with J.H. Darbie by issuing 400 shares of Series D Convertible Preferred Stock and agreeing to pay $175,000 in cash installments. Separately, the majority stockholder (Rennova Health, controlled by the CEO) approved a reverse stock split of 1:1,000 to 1:10,000, to be effected at the Board's discretion before November 30, 2026. The reverse split signals a distressed equity structure and potential NASDAQ compliance effort, while the settlement removes a creditor overhang but introduces future dilution risk.

Actionable Insight

The reverse stock split at a ratio up to 1:10,000 signals severe equity distress and likely efforts to maintain listing. Monitor for the definitive information statement and FINRA approval timeline. The settlement with J.H. Darbie removes immediate creditor pressure but introduces convertible preferred dilution. The CEO-controlled majority stockholder's 95.56% voting control means minority shareholders have no influence over the reverse split terms.

Key Facts

  • Settlement with J.H. Darbie resolves all amounts owed under finder's fee, advisory, and private placement agreements.
  • Company issued 400 shares of Series D Convertible Preferred Stock (convertible into common) and will pay $175,000 in seven monthly installments of $25,000.
  • Payment default triggers conversion of unpaid balance into common stock at 90% of 20-day VWAP, subject to 4.99% beneficial ownership cap.
  • Majority stockholder (Rennova Health, controlled by CEO) holding ~95.56% voting rights approved a reverse stock split of 1:1,000 to 1:10,000.
  • Reverse split must be effected before November 30, 2026, at Board's discretion; prior 2025 reverse split authorization was abandoned.
  • Reverse split is subject to FINRA approval and will be effective no earlier than 20 days after mailing of definitive information statement.

Financial Impact

Cash payment of $175,000 over seven months; potential dilution from conversion of Series D Preferred Stock and default-conversion rights at 90% of VWAP.

dilutiondebtcash

Risk Factors

  • Extreme reverse split ratio (up to 1:10,000) could crush liquidity and trigger further price declines.
  • Conversion of Series D Preferred and potential default-conversion rights create uncertain dilution overhang.
  • Cash payment obligations ($175,000) strain limited liquidity for a pre-revenue company.
  • Prior reverse split authorization was abandoned, suggesting execution risk or worsening conditions.

Market Snapshot

Exchange
OTC
Sector
Services-Commercial Physical & Biological Research

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-025076
Document: 0001493152-26-025076-index-headers.html0001493152-26-025076
Document: 0001493152-26-025076-index.html0001493152-26-025076
Document: 0001493152-26-025076.txt0001493152-26-025076
3 reports for FOXOW
Performance horizon
Filters
Rows
Reports for FOXOW — sortable, filterable
Type Now
May 28, 2026
15d ago
8-K
NEUTRAL ★ 4/10
awaiting T+20
May 22, 2026
21d ago
8-K
BEARISH ★ 6/10
awaiting T+20
May 18, 2026
26d ago
8-K
MIXED ★ 6/10
awaiting T+20
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (48h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access